Johnson & Johnson (NYSE: JNJ) released survey results showing that more than 90% of bladder cancer patients who underwent bladder removal surgery or received BCG treatment reported negative impacts on multiple aspects of their lives.

The Harris Poll conducted the survey on behalf of Johnson & Johnson in collaboration with bladder cancer organizations, examining experiences of 817 patients with non-muscle-invasive bladder cancer and 802 urologists across six countries between November and December 2025.

Among patients treated with BCG, 76% described managing treatment-related physical symptoms as humiliating, while 80% reported loss of control over their body and 69% experienced loss of dignity or sense of self.

The survey found that 94% of patients reported missing life moments due to treatment, with more than one-third avoiding socializing with friends and family, leaving home, or going out in public. Depression and anxiety drove nearly half of these missed moments.

About three-quarters of patients said they hide the emotional impact of their disease, with one-third always or often concealing their feelings. Additionally, 86% reported constantly worrying about cancer recurrence.

Among patients who underwent radical cystectomy, more than 90% reported negative impacts on physical, mental and emotional health, daily activities, body image and self-esteem, with more than half describing impacts as moderate or significant.

The survey revealed that 78% of urologists wish they could dedicate more time to discussing mental and emotional impacts during appointments, while 90% said they wish there were better ways to address these impacts.

Nearly 40% of urologists who had recommended bladder removal surgery reported regretting the recommendation, according to expert commentary included with the survey results.

Both patients and urologists expressed interest in new treatment approaches beyond current standard-of-care options, the survey found.